FDA approved axatilimab-csfr for chronic graft-versus-host disease in August 2024Nov 6Regulatory decisionaxatilimab-csfrIncyte Corporation
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Syndax reports Q3 2026 results, 90% Revuforj revenue growth, CFO transitionNov 2Quarterly updaterevumenibSyndax Pharmaceuticals Inc
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
Syndax reports 2Q26 revenue growth, details EGFR and menin inhibitor pipeline additionsAug 4Quarterly updaterevumenibSyndax Pharmaceuticals Inc
Incyte raises 2026 sales guidance, adds ten data readouts, closes Vega dealJul 28Quarterly updateIncyte Corporation